Skip to main content

Ernexa Therapeutics Inc.

corporate_fare Company Profile

Ernexa Therapeutics Inc.

ERNA·NASDAQ·Life Sciences·CIK 0000748592

The company is a preclinical-stage company focused on synthetic allogeneic iMSC therapy. iMSCs are mesenchymal stem cells derived from induced pluripotent stem cells. The company aims to develop scalable, affordable, off-the-shelf cell therapies for cancer and autoimmune disease. Its lead product candidate, ERNA-101, consists of allogeneic IL-7 and IL-15-secreting iMSCs. ERNA-101 is designed to target tumors and deliver pro-inflammatory factors directly to the tumor microenvironment, potentially enhancing T-cell anti-tumor activity while limiting systemic exposure and toxicity. The initial development focus for ERNA-101 is platinum-resistant ovarian cancer. In a preclinical study with the University of Texas MD Anderson Cancer Center, ERNA-101 reduced tumor growth and showed a statistically significant survival advantage in an ovarian cancer model compared to a control group. In the fourth quarter of 2025, the company had a successful pre-Investigational New Drug (IND) meeting with the Food and Drug Administration (FDA). The company is also investigating ERNA-201, which are anti-inflammatory cytokine (e.g., IL-10)-secreting iMSCs, for autoimmune disorders such as rheumatoid arthritis.

Ernexa Therapeutics Inc. (NASDAQ:ERNA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for ERNA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-06, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for ERNA spans 10-Q, 8-K, DEFA14A, DEF 14A.

Recent high-impact activity:

  • Ernexa Q3 2026: $5.6M Cash, Going-Concern Warning, $12.5M Nine-Month Loss
  • Ernexa's ERNA-101 Clears Key Safety Hurdles, IND Filing Set for Q4
  • Ernexa's ERNA-201 Shows Disease-Modifying Activity in Arthritis Model, Paving Way for ERNA-101 IND
  • Ernexa Q2 2026: Cash Drops to $5M, Going Concern Relies on ATM Sales; Nasdaq Compliance Regained but Under Monitor
  • Independent Study Shows ERNA-101 Combo Clears Tumors in 67% of Ovarian Cancer Models

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$14.08M
Diluted EPS
-$2.24
Op. Cash Flow
-$7.02M
Free Cash Flow
-$7.05M
Operating Income
-$9.32M
Cash & Equivalents
$1.88M
Debt / Equity
0.00×
Shares Outstanding
7.85M sh
Source: 10-K · filed 2026-03-13 · accession 0001493152-26-010102

Short Interest & Short Volume

2.03 days to cover

FINRA reported short interest of 33,263 shares in ERNA as of the October 30, 2026 settlement, a 67.3% increase from the prior period — about 2.0 days to cover at its recent average daily volume. On November 20, 2026, 25.0% of ERNA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)33,263 shares as of October 30, 2026
Change vs prior period▲ 67.3%
Days to cover2.03 at avg daily volume of 16,424
Daily short volume (FINRA facilities)25.0% of 14,975 shares on November 20, 2026
5-day average short volume35.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with E →
$1.63
52-week range · as of 2026-11-06 $1.63 – $46.11
Market cap
$2.3M
Volume
20.4K (1.2× avg)
3-mo avg 17.2K
Live data · 2026-11-22 12:35 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ERNA - Latest Insights

ERNA
Nov 06, 2026, 4:50 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.88
Real-time Price: $1.63 info
Change: -$0.250 (-13%) info
Market Cap: $2.302M info
ERNA
Sep 30, 2026, 8:32 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.52
Real-time Price: $1.63 info
Change: -$1.89 (-54%) info
Market Cap: $2.302M info
ERNA
Sep 15, 2026, 8:42 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.54
Real-time Price: $1.63 info
Change: -$1.91 (-54%) info
Market Cap: $2.302M info
ERNA
Aug 06, 2026, 5:31 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.57
Real-time Price: $1.63 info
Change: -$2.94 (-64%) info
Market Cap: $2.302M info
ERNA
Jul 15, 2026, 7:50 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $11.04
Real-time Price: $1.63 info
Change: -$9.41 (-85%) info
Market Cap: $2.302M info
ERNA
Jul 02, 2026, 4:40 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.20
Real-time Price: $1.63 info
Change: -$4.57 (-74%) info
Market Cap: $2.302M info
ERNA
Jul 02, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.20
Real-time Price: $1.63 info
Change: -$4.57 (-74%) info
Market Cap: $2.302M info
ERNA
Jun 17, 2026, 8:47 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $6.29
Real-time Price: $1.63 info
Change: -$4.66 (-74%) info
Market Cap: $2.302M info
ERNA
May 27, 2026, 8:11 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $11.69
Real-time Price: $1.63 info
Change: -$10.06 (-86%) info
Market Cap: $2.302M info
ERNA
May 11, 2026, 5:12 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $7.37
Real-time Price: $1.63 info
Change: -$5.74 (-78%) info
Market Cap: $2.302M info
ERNA
May 11, 2026, 5:11 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $7.37
Real-time Price: $1.63 info
Change: -$5.74 (-78%) info
Market Cap: $2.302M info
ERNA
May 11, 2026, 5:09 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $7.37
Real-time Price: $1.63 info
Change: -$5.74 (-78%) info
Market Cap: $2.302M info
ERNA
May 11, 2026, 5:02 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.37
Real-time Price: $1.63 info
Change: -$5.74 (-78%) info
Market Cap: $2.302M info
ERNA
May 06, 2026, 8:33 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $6.04
Real-time Price: $1.63 info
Change: -$4.41 (-73%) info
Market Cap: $2.302M info
ERNA
May 04, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.88
Real-time Price: $1.63 info
Change: Reverse Stock Split info
Market Cap: $2.302M info
ERNA
Apr 30, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.1432
Real-time Price: $1.63 info
Change: Reverse Stock Split info
Market Cap: $2.302M info
ERNA
Apr 13, 2026, 9:28 AM EDT
Filing Type: DEF 14C
Importance Score:
8
Price at Filing: $0.1951
Real-time Price: $1.63 info
Change: Reverse Stock Split info
Market Cap: $2.302M info
ERNA
Apr 01, 2026, 5:23 PM EDT
Filing Type: PRE 14C
Importance Score:
8
Price at Filing: $0.2012
Real-time Price: $1.63 info
Change: Reverse Stock Split info
Market Cap: $2.302M info
ERNA
Mar 31, 2026, 8:55 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $0.2039
Real-time Price: $1.63 info
Change: Reverse Stock Split info
Market Cap: $2.302M info
ERNA
Mar 20, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.2604
Real-time Price: $1.63 info
Change: Reverse Stock Split info
Market Cap: $2.302M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets